Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI) diseases. The Company was established by experienced specialty pharmaceutical executives with a successful track record of acquiring, developing, registering, and marketing pharmaceutical products in the US.
Evoke has concentrated on the gastroenterology field due to the significant unmet medical needs, the opportunity to improve known products and its focused physician base. Despite the relatively high number of patients suffering from gastrointestinal diseases and disorders, there are only about 12,000 gastroenterologists in the U.S. These physicians conduct over 31 million patient visits and write almost 40 million prescriptions each year. Also, GI diseases may limit or alter the effectiveness of traditional oral therapies due to the disease for which the product is intended to treat. By developing enhanced versions of currently approved drug products, through novel delivery formats or formulations, Evoke intends to provide patients additional treatment options.
Evoke’s lead product candidate, Gimoti, has been submitted for FDA review under a 505(b)(2) New Drug Application with an April 1, 2019 Prescription Drug User Fee Act (PDUFA) target goal date. The product is intended for the treatment of diabetic gastroparesis.
Evoke has advanced its product development activities by leveraging several corporate relationships with many external clinical, CMC, and regulatory experts. Evoke plans to continue this strategy of developing acquired products in partnership with various global organizations depending upon new acquisitions and appropriate asset investment.